Vanguard Global Advisers’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$295K Buy
61,802
+6,650
+12% +$32K ﹤0.01% 2325
2026
Q2
$265K Hold
55,152
– – ﹤0.01% 2382
2026
Q1
$248K Buy
+55,152
New +$241K ﹤0.01% 2334

Other funds holding ABUS

Vanguard Global Advisers's ABUS Position: Q3 2026 in Review

Vanguard Global Advisers increased its Arbutus Biopharma (ABUS) stake by 12% in Q3 2026, buying an estimated $32K and bringing the position to 61,802 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

Vanguard Global Advisers first reported a position in ABUS in Q1 2026 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Vanguard Global Advisers held 61,802 shares of Arbutus Biopharma worth $295K as of Q3 2026.
  • Vanguard Global Advisers bought 6,650 Arbutus Biopharma shares in Q3 2026, an estimated $32K.
  • Arbutus Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2325 holding.
  • Vanguard Global Advisers first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 3 quarters since.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.